John W. Sweetenham, MD | Authors

Articles

Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation

November 15, 2016

Although ibrutinib-related atrial fibrillation (IRAF) occurs in up to 11% of patients in clinical trials, these studies have rarely fully characterized bleeding events or risk factors for bleeding when ibrutinib is combined with anticoagulation. Furthermore, guidelines do not provide direction regarding the preferred anti-arrhythmic agent for IRAF.

Surviving Surveillance

April 15, 2015

The message seems to be emerging that for some diseases, clinical monitoring for relapse and recurrence has a strong evidence base, is safe, and is associated with lower costs.

Treatment of Lymphoblastic Lymphoma in Adults

November 10, 2009

Lymphoblastic lymphoma (LBL) is a rare disease, comprising about 2% of all non-Hodgkin lymphomas (NHLs) in adults.[1] It is a highly aggressive subtype of lymphoma, most commonly of precursor T-cell origin, occurring most frequently in adolescents and young adults, with male predominance and frequent mediastinal, bone marrow, and central nervous system (CNS) involvement.

Hodgkin Lymphoma in Older Patients: An Uncommon Disease in Need of Study

November 15, 2008

Hodgkin lymphoma (HL) is one of the most curable malignancies in adults. However, survival rates for elderly patients with HL (often defined as ≥ 60 years of age) are inferior to those achieved by younger populations.

Commentary (Sweetenham): Lymphoma 2006: Classification and Treatment

March 01, 2006

The past 20 years have brought significant advances in our ability to manage patients with non-Hodgkin's lymphoma. More precise classification systems, improvements in diagnosis and staging, and effective new treatments have improved outcomes and made cure a reasonable goal for many patients with these disorders.

Hematopoietic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma

May 01, 2003

We have seen major advancesin our understanding ofthe biology of malignantlymphoma in recent years. These advanceshave been reflected in thedevelopment of the Revised European-American (REAL)/World HealthOrganization (WHO) classificationof lymphoid malignancies, which incorporatesdata from immunophenotype,cytogenetic, and moleculargenetic studies as well as morphologicappearance and clinical behavior.The description of DNAmicroarray studies in diffuse largeB-cell non-Hodgkin’s lymphoma(NHL) has already generated usefulprognostic data and identified manypotential therapeutic targets.[1] Futurestudies may provide pharmacogenomicdata, which could predictresponse to therapy in individual patients,and thus allow a more tailoredtreatment approach.